Amredobresib (BI894999) is an orally active BET inhibitor. Amredobresib inhibits the binding of BRD4-BD1 and BRD4-BD2 bromodomains to acetylated histones with IC50 values of 5 nM and 41 nM, respectively. Amredobresib exhibits anticancer activity against acute myeloid leukemia (AML) and NUT cancer[1][2][3][4][5].
Molecular Weight:
467.57
Purity:
98.97
CAS Number:
[1610044-98-8]
Formula:
C26H29N9
Target:
Epigenetic Reader Domain
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted